Brind.

Silo sought the FDA's 505(b)(2) regulatory pathway and completed a safety study.

2 reports, 1 independent Updated Jul 16

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Silo sought the FDA's 505(b)(2) regulatory pathway and completed a safety study.

Who's involved

What this event is mainly about

FDA Silo

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Silo
Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 16GlobeNewswireSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmen
Jul 7Unknown outlet